MDS
Advertisement
The favorable effects from pharmacologic iron restriction may also be enhanced when used with an erythroid maturation agent.
Analysts advise that CMML that features AML-associated mutations should undergo management approaches typically used for AML.
Expert panel consensus produced a set of genomics-based disease categories from the two systems' morphology-based categories.
Clinicians seek alternatives to biopsy for clinically evaluating bone marrow mutations in cytopenic patients.
A retrospective study's insights help inform timing decisions regarding allogenic HCT in patients with MDS or CMML.
Investigators examined patients' baseline transfusion burdens and erythropoietin levels for correlations with agent response.
The COMMANDS trial data underscore luspatercept as the preferred treatment for disease not previously exposed to ESAs.
A phase II trial evaluated use of the thrombopoietin receptor agonist in patients with at least one prior therapy.
Most of the research performed up to this point on the influence of clonal dynamics in MDS has focused on high-risk disease.
A majority of patients in the study had complete remission of disease within bone marrow with the combination therapy.
Levels for certain inflammation biomarkers in patients with MDS were similar to in patients with autoinflammatory disorders.
In pediatric, adolescent, and young adult patients, hematopoietic stem cell transplant was found to bolster overall survival.
The most common serious treatment-emergent adverse event among patients receiving either therapy was pneumonia.
A study has observed these genetic influences on disease outcome in MDS with isolated deletion of chromosome 5q.
The trial outcomes did not meet statistical significance but suggest transfusion independence achievement and good tolerance.
Phase III trial findings on MDS with chromosome 5q deletion also included improved treatment response and favorable safety.
Analysis of patients' IPSS-R scoring and bone marrow blast presence found limited benefit from pretransplant interventions.
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
Phase II study data demonstrate this benefit in patients with low-risk myeloid malignancies or precursor conditions.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.